← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › ALKYLATING AGENTS › Ethylene imines
triaziquone
L01AC02
Forms & Strengths
- Injection: 10mg/mL
- Solution for injection: 10mg/mL
Adult Dosing
- 60mg/m² intravenously on days 1, 3, and 5
- Dose reduction for renal impairment may be required
- Dose adjustment for hepatic impairment may be needed
Pediatric Dosing
- Safety and efficacy in pediatric patients not established
Indications
- Treatment of ovarian cancer
- Palliative treatment of multiple myeloma
- Investigational use in other types of cancer
Mechanism of Action
- Alkylating agent, forming covalent bonds with DNA
- Interfering with DNA replication and transcription
- Inducing cross-links in DNA, leading to cell death
Contraindications
- Severe bone marrow suppression
- Pregnancy and lactation
- Hypersensitivity to triaziquone or its components
Adverse Reactions
- Myelosuppression, thrombocytopenia, and anemia
- Nausea, vomiting, and gastrointestinal disturbances
- Alopecia, dermatitis, and other skin reactions
Drug Interactions
- Cimetidine may increase triaziquone toxicity
- Phenytoin may decrease triaziquone efficacy
- Concomitant use with other myelosuppressive agents may increase toxicity
Curated Content: Needs Vetting Before Put to Clinical Use